IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.
IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.
Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.
| Name of the Company | IPGaia, Inc. | |
|---|---|---|
| Location | 2-5-1 Atago, Minato-ku, Tokyo 105-6236 | |
| Investor | Healthcare New Platform Fund（100％） General Partner; Whiz Partners Inc. | |
| Capital and Capital Reserves | 10 million JPY | |
| Established | October 26th, 2021 | |
| Business Scope |
| |
| Management | Chairperson President & CEO | Yuki Hasegawa Yasunori Yamaguchi |
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and the University of Miami have entered into an agreement where University of Miami presents potential drug candidates for development with IPG. This Agreement enables the University of Miami to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of research institutions, including global academia and pharmaceutical companies. IPG continues to expand steadily both domestically and internationally, with the University of Miami joining as the eleventh academic institution (Five institutions in Japan, five institutions in the …
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and the Icahn School of Medicine at Mount Sinai (“Icahn Mount Sinai”) have entered into a Comprehensive Collaborative Research and Development Agreement (“this agreement”) dated August 7th, 2024. This agreement establishes a formal framework for the incorporation of promising drug target leads from Icahn Mount Sinai into IPG’s drug discovery platform. This agreement enables Icahn Mount Sinai to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of research institutions, including global academia and pharmaceutical companies, …
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) has entered into a Master Collaborative Research and Development Agreement (“this agreement”) with Tohoku University. This agreement is intended to propose drug discovery seeds handled by Tohoku University Hospital (Sendai, Miyagi Prefecture, Japan; Hospital Director: Hideo Harigae, “Tohoku University Hospital”)※1, regarding IPG platform for efficient generation of high-quality new drugs. This agreement enables IPG to receive proposals for drug discovery seeds handled by Tohoku University Hospital. IPG pursues the joint research program with Tohoku University for identification and development of clinical development candidates with the goal of licensing them to pharmaceutical companies. IPG is soliciting drug discovery seeds from a wide range of …
